Vertex Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: VRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vertex Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Vertex Pharmaceuticals generated $1.13 billion of operating cash flow and spent $112.2 million on capital expenditures. That left free cash flow of $1.01 billion, a free-cash-flow margin of 30.4% of revenue. Free cash flow was up 9.3% from the prior year's $927.4 million.
Vertex Pharmaceuticals returned $469.5 million to shareholders through share repurchases, equal to 46% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Vertex Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.10B | 1.03B | 1.19B | 1.08B | 1.03B | 646.30M | 913.00M | 1.05B | -3.59B | 1.10B | 968.80M | 1.04B |
| Net Income growth (YoY) | +6.48% | +59.59% | +30.46% | +3.59% | — | -41.22% | -5.76% | +0.98% | -492.44% | +57.13% | +18.31% | +11.26% |
| Depreciation & Amortization | 56.50M | 55.90M | 55.70M | 54.00M | 51.70M | 48.40M | 46.50M | 53.20M | 54.00M | 53.50M | 59.00M | 42.10M |
| Stock-Based Compensation | 170.20M | 166.40M | 157.60M | 194.90M | 167.30M | 166.10M | 167.80M | 184.60M | 154.20M | 191.90M | 208.60M | 130.90M |
| Change in Working Capital | -337.50M | 174.20M | -283.30M | -183.30M | -299.00M | -316.60M | -240.10M | -13.10M | -409.70M | -64.80M | -482.20M | -179.80M |
| Operating Cash Flow | 1.13B | 1.43B | 498.00M | 1.24B | 1.07B | 818.90M | 584.60M | 1.37B | -3.75B | 1.31B | 234.60M | 1.27B |
| Capital Expenditures | -112.20M | -133.40M | -149.40M | -101.80M | -145.70M | -40.70M | -92.60M | -67.70M | -69.00M | -68.40M | -58.10M | -40.60M |
| Investing Cash Flow | -45.80M | -431.90M | -288.10M | -117.00M | -484.50M | -55.80M | -821.90M | -348.00M | -463.70M | -2.14B | -886.50M | -117.70M |
| Share Repurchases | -469.50M | -336.90M | -128.40M | -1.07B | -391.80M | -426.10M | -417.90M | -307.70M | -320.30M | -131.20M | -149.50M | -117.00M |
| Financing Cash Flow | -426.70M | -538.80M | -77.20M | -1.15B | -349.20M | -680.40M | -391.30M | -387.50M | -358.60M | -357.50M | -119.80M | -165.00M |
| Net Change in Cash | 649.20M | 417.10M | 140.00M | -34.20M | 296.60M | 113.20M | -675.90M | 657.10M | -4.58B | -1.20B | -744.30M | 963.20M |
| Free Cash Flow | 1.01B | 1.29B | 348.60M | 1.14B | 927.40M | 778.20M | 492.00M | 1.30B | -3.82B | 1.24B | 176.50M | 1.23B |
This table shows 12 quarterly periods of Vertex Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VRTX's reporting calendar. What is a cash flow statement?